HIV Prevention Shot Lenacapavir: Aspen Warns of Demand Risks
Learn about the HIV prevention shot lenacapavir and why Aspen Pharmacare emphasises guaranteed demand for local production.
Aspen Pharmacare Asset Disposals: Future Opportunities
Learn about potential Aspen Pharmacare asset disposals aimed at optimising the company's global operations for greater profitability.
Aspen Pharmacare Debt-Free: Strategic Shift To GLP-1 Injectables
Aspen Pharmacare Debt-Free marks a pivotal moment in its history as it shifts focus toward GLP-1 injectables like semaglutide.
Local Pharmaceutical Manufacturing for Future Sustainability
… Membership Required You must be a member to access this content.View Membership LevelsAlready a member? Log in here...
AIDS Drug Tender: Pressure as Suppliers Enter Business Rescue
The AIDS drug tender reveals challenges in supply continuity due to Avacare subsidiaries entering business rescue.
Generic Semaglutide Set to Disrupt Global GLP‑1 Market
Aspen Pharmacare is lining up a generic semaglutide launch in Canada, promising big discounts, and widening GLP-1 access.
Aspen Pharmacare Business Sale Sparks Investor Optimism
Aspen Pharmacare business sale boosts investor confidence. A strategic pivot following a turbulent 2025 rebuilds financial flexibility.
Aspen APAC Divestment Unlocks R26.5 Billion For GLP-1 Focus
Aspen APAC divestment unlocks R26.5bn in capital, sharpening the group’s focus on GLP-1 injectables and reducing net debt heading into 2026.
HIV Prevention in SA Needs Local Lenacapavir Manufacturing
HIV prevention in South Africa hinges on local drug manufacturing to ensure access, reduce delays, and enable regional health security.
Aspen Pharmacare Dispute Ends with R500m Settlement
Aspen Pharmacare resolves its mRNA dispute with a R500m settlement, stabilising its earnings and share price significantly.